Overview

Venous Thromboembolism Prevention in Outpatients With Glioma

Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Vermont Medical Center
Collaborators:
Dartmouth-Hitchcock Medical Center
MaineHealth
Treatments:
Apixaban